Scarica l'app Stockscreener
10.42
3.43%
-0.37
Dopo l'orario di chiusura:
10.46
0.04
+0.38%
Precedente Chiudi:
$10.79
Aprire:
$10.7
Volume 24 ore:
449.16K
Relative Volume:
0.97
Capitalizzazione di mercato:
$509.44M
Reddito:
$251.00K
Utile/perdita netta:
$-87.07M
Rapporto P/E:
-2.9357
EPS:
-3.5494
Flusso di cassa netto:
$-80.18M
1 W Prestazione:
-6.34%
1M Prestazione:
-7.13%
6M Prestazione:
+71.38%
1 anno Prestazione:
+285.93%
Intervallo 1D:
$10.36
$10.93
Intervallo di 1 settimana:
$10.36
$11.34
Portata 52W:
$2.22
$14.53
Artiva Biotherapeutics Inc Stock (ARTV) Company Profile
Nome
Artiva Biotherapeutics Inc
Settore
Industria
Telefono
(858) 267-4467
Indirizzo
5505 MOREHOUSE DRIVE, SAN DIEGO
Compare ARTV vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARTV
Artiva Biotherapeutics Inc
|
10.42 | 527.52M | 251.00K | -87.07M | -80.18M | -3.5494 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Artiva Biotherapeutics Inc Stock (ARTV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-11 | Ripresa | H.C. Wainwright | Buy |
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Iniziato | Jefferies | Buy |
| 2024-08-13 | Iniziato | Needham | Buy |
| 2024-08-13 | Iniziato | TD Cowen | Buy |
| 2024-08-13 | Iniziato | Wedbush | Outperform |
Mostra tutto
Artiva Biotherapeutics Inc Borsa (ARTV) Ultime notizie
Artiva Biotherapeutics (ARTV) CEO Fred Aslan Sells 23,429 Shares - GuruFocus
Artiva Biotherapeutics CEO Fred Aslan Executes Sale of 23,429 Shares Under 10b5-1 Plan - Kalkine Media
ARTV: Pivotal phase III trial in refractory RA advances, aiming for first-in-class deep B-cell depletion - TradingView
Artiva Biotherapeutics at cantor healthcare conference: ra push gains ground By Investing.com - Investing.com Canada
ARTV: Pivotal phase III trial for refractory RA advances, with robust enrollment and data updates expected - TradingView
Artiva Biotherapeutics CEO Aslan Fred Offloads 61,888 Shares at $11.16 on September 3, 2026 (NASDAQ: ARTV) - Kalkine Media
Artiva Biotherapeutics CTO Horan Christopher Disposes of 10,366 Shares at $11.16 Each (NASDAQ: ARTV) - Kalkine Media
Artiva initiates phase 3 trial for refractory arthritis therapy By Investing.com - Investing.com Canada
Artiva initiates phase 3 trial for refractory arthritis therapy - Investing.com
Artiva Biotherapeutics Provides Update On Planned Allonk® Data Disclosures And Development Milestones For The Remainder Of 2026 - TradingView
Artiva Biotherapeutics Announces Planned 2026 Data Readouts and Phase 3 Trial Initiation for AlloNK in Refractory Rheumatoid Arthritis - Quiver Quantitative
Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026 - Yahoo! Finance Canada
Have Insiders Sold Artiva Biotherapeutics Shares Recently? - simplywall.st
Artiva Biotherapeutics CEO Fred Aslan Sells 61,888 Shares in Tax-Related Sell-to-Cover Transaction - Kalkine Media
Artiva Biotherapeutics COO Jennifer Bush Executes Share Sale for Tax Withholding Purposes - Kalkine Media
Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying - Benzinga
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September - GlobeNewswire
Artiva Biotherapeutics CMO Subhashis Banerjee sells $98,735 in shares By Investing.com - Investing.com Australia
Artiva Biotherapeutics CMO Subhashis Banerjee Executes Stock Option Exercise and Sells Shares via 10b5-1 Plan - Kalkine Media
Artiva Biotherapeutics CMO Subhashis Banerjee sells $98,735 in shares - Investing.com
ARTV News | ARTIVA BIOTHERAPEUTICS INC (NASDAQ:ARTV) - ChartMill
ARTV Q2 2026 Earnings: Slightly Narrower Loss Delivers a Modest BeatOperating Income Trends - vinanet.vn
Artiva Biotherapeutics CMO Subhashis Banerjee disposes of 429 common shares worth $5,148 under 10b5-1 plan - Bitget
Artiva (ARTV) Earnings Update: The Bottom-Line Figure Outpaces Its Comparison on the Day; Post-Report: The Market Price Moves 0.17% Higher for the Current SessionEPS Revision Trend - vinanet.vn
Artiva Biotherapeutics CMO sells $5,148 in stock By Investing.com - Investing.com South Africa
Artiva Biotherapeutics CMO sells $5,148 in stock - Investing.com
Artiva Biotherapeutics: Targeting A Potentially Lucrative Niche (NASDAQ:ARTV) - Seeking Alpha
ARTV Q2 2026 Earnings: Narrower Loss of $0.63 per Share, But Stock Slips 0.35%Debt Analysis Report - vinanet.vn
What is HC Wainwright's Forecast for ARTV Q3 Earnings? - MarketBeat
Artiva Biotherapeutics (ARTV) Slips to $11.22 as Stock Holds Above Key SupportSmart Beta Flow - dars.gov.et
Artiva Biotherapeutics (ARTV) Edges Down 0.44% to $11.22, Trading Between Key Support and ResistanceVolatility Smile - dars.gov.et
Wall Street Zen Upgrades Artiva Biotherapeutics (NASDAQ:ARTV) to Hold - MarketBeat
TD Cowen Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating, Announces Target Price $11.58 - Moomoo
H.C. Wainwright Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating, Maintains Target Price $35 - Moomoo
ARTIVA BIOTHERAPEUTICS INC: QTRLY EPS $-0.63 - webull.com
Artiva Therapeutics: Buy Rating Reiterated on Strong AlloNK RA Profile and Upcoming Phase III, Price Target Maintained at $41 - TipRanks
Artiva Therapeutics: Buy Rating Reiterated on Promising RA Data, Clear Phase 3 Path and Maintained $35 Price Target - TipRanks
Certain Restricted Stock Units of Artiva Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-AUG-2026. - marketscreener.com
Certain Stock Options of Artiva Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-AUG-2026. - marketscreener.com
Artiva Biotherapeutics (NASDAQ:ARTV) Announces Quarterly Earnings Results - MarketBeat
Artiva Biotherapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights - The Manila Times
Artiva Biotherapeutics reports Q2 2026 net loss $25.0M, cash $349.4M to fund operations into 2029 - TradingView
FDA RMAT designation for AlloNK plus rituximab boosts Artiva Biotherapeutics, Inc. clinical progress - Traders Union
Artiva Biotherapeutics stock surges on positive trial data By Investing.com - Investing.com Nigeria
Form DEF 14A Artiva Biotherapeutics For: 3 August By Investing.com - Investing.com Nigeria
Ra capital management, 10% owner, acquires $455,725 Artiva stock By Investing.com - Investing.com Nigeria
Form 4 Artiva Biotherapeutics Inc For: 1 August By Investing.com - Investing.com UK
Artiva Biotherapeutics (NASDAQ:ARTV) Director Purchases $247,693.92 in Stock - MarketBeat
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Ra capital management director buys $412,776 in Artiva Biotherapeutics By Investing.com - Investing.com Nigeria
Artiva Biotherapeutics Inc Azioni (ARTV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):